{"createdAt":"8/2/2020, 2:08:23 PM","timestamp":1596391703031,"Company ID number":"352","DMX_ISSUER_NAME":"Jafron Biomedical Co Ltd","DMX_ISSUER_ID":"IID000000002770486","Country of Classification":"CHINA","name":"Jafron Biomedical Co Ltd ","code":"300529","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"健帆生物科技集团股份有限公司_董凡","group":"board","name":"董凡","title":"董事长,董事","isMale":true,"age":"50","degree":"硕士","salary":"210.1万","stockAmount":"3.508亿","description":"董凡先生:1970年生,中国国籍,无境外永久居留权,上海财经大学本科学历,中山大学企业管理专业研究生学历。1992年至1999年在珠海丽珠医药集团股份有限公司从事营销及管理工作,1999年进入健帆生物科技集团股份有限公司负责公司全面经营管理工作。曾获得国家科技进步二等奖、天津市科技进步二等奖、珠海市科技进步一等奖等多项荣誉。2011年,当选为珠海市人大代表。2012年,当选为中共广东省党代会代表。2016年,当选为珠海市工商联主席、珠海市总商会会长,荣获“广东省优秀中国特色社会主义事业建设者”荣誉称号。2017年,当选为中华全国工商业联合会执行委员、广东省工商业联合会(总商会)执行委员会副主席、珠海市人大常委会委员,入选“广东特支计划”科技创业领军人才、“科技部创新人才推进计划科技创新创业人才”,被珠海市政府聘为“珠海市决策咨询委员会顾问”。2018年,入选“国家万人计划科技创业领军人才”,当选为政协广东省委员会委员,获评“广东省五一劳动奖章”。现任健帆生物科技集团股份有限公司董事长、总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_曾凯","group":"board","name":"曾凯","title":"董事","isMale":true,"age":"45","degree":"本科","salary":"100.9万","stockAmount":"53.6万","description":"曾凯先生:1975年生,中国国籍,无境外永久居留权,武汉工业大学本科学历。2008年进入健帆生物科技集团股份有限公司,历任采购供应部经理、企业管理部经理、人事行政中心总监、生产总监,现任健帆生物科技集团股份有限公司董事、副总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_唐先敏","group":"board","name":"唐先敏","title":"董事","isMale":false,"age":"50","degree":"本科","salary":"137.6万","stockAmount":"2457万","description":"唐先敏女士:1970年生,中国国籍,无境外永久居留权,成都体育学院运动医学专业本科学历。曾先后任职于丽珠集团丽珠保健品厂、美国西尔药厂,从事营销工作。1999年8月加入健帆生物科技集团股份有限公司,历任办事处经理、大区经理、事业部副总监、市场总监。曾获得珠海市科技进步一等奖、珠海市“三八”红旗手、珠海市高层次人才。现任健帆生物科技集团股份有限公司董事、副总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_张广海","group":"board","name":"张广海","title":"董事","isMale":true,"age":"56","degree":"硕士","salary":"72.41万","stockAmount":"557.1万","description":"张广海先生:1964年生,中国国籍,无境外永久居留权,齐齐哈尔大学本科学历,中山大学企业管理专业研究生学历,高级工程师。2001年加入健帆生物科技集团股份有限公司,历任生产部经理、总经理助理。曾获得国家科技进步二等奖、天津市科技进步二等奖、珠海市科技进步一等奖、珠海市高层次人才。担任全国医用体外循环设备标准化技术委员会委员,现任健帆生物科技集团股份有限公司董事、副总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_李峰","group":"board","name":"李峰","title":"董事","isMale":true,"age":"50","degree":"硕士","salary":"49.00万","stockAmount":"104.3万","description":"李峰先生:1970年生,中国国籍,无境外永久居留权,广州华南理工大学本科学历、学士学位,中山大学研究生学历。曾任珠海丽珠集团丽珠医用生物材料厂总经理助理、销售部经理,珠海力拓发展有限公司副总经理,珠海和佳医疗设备股份有限公司市场策划部经理。2010年进入健帆生物科技集团股份有限公司,现任健帆生物科技集团股份有限公司董事、总经理助理。","lastUpdated":"2020-04-28"},{"id":"健帆生物科技集团股份有限公司_雷雯","group":"board","name":"雷雯","title":"董事","isMale":false,"age":"49","degree":"硕士","salary":"--","stockAmount":"-","description":"雷雯女士:1971年生,中国国籍,无境外永久居住权,中共党员。1992年本科毕业于上海财经大学金融系保险专业,2000年毕业于北京大学光华管理学院、研究生学历、硕士学位。本科毕业后先后在中国平安,AIG旗下美亚财产保险公司等公司工作任职。2002年至2012年,任职于太平洋财产保险股份有限公司广东省分公司,历任市场部经理,核保部经理,珠海公司副总经理、总经理兼党委书记。现为若水轩(横琴)文化发展有限公司创始人、广东省天行健慈善基金会荣誉会长、广东省书法家协会会员、深圳家云智能科技有限公司董事长。","lastUpdated":"2020-04-28"},{"id":"健帆生物科技集团股份有限公司_杨柏","group":"board","name":"杨柏","title":"独立董事","isMale":true,"age":"58","degree":"博士","salary":"9.600万","stockAmount":"-","description":"杨柏先生:1962年12月出生,中国国籍,无境外永久居留权,博士研究生学历,教授、博士研究生导师、教育部长江学者、国务院政府特殊津贴专家。1991年12月起任职于吉林大学,现任吉林大学化学学院教授,并担任吉林省化学会副理事长、中国材料研究学会高分子材料与工程分会常务理事、中国材料研究学会纳米材料与器件分会理事、深圳市沃特新材料股份有限公司独立董事。现任健帆生物科技集团股份有限公司独立董事。","lastUpdated":"2020-04-28"},{"id":"健帆生物科技集团股份有限公司_周凌宏","group":"board","name":"周凌宏","title":"独立董事","isMale":true,"age":"55","degree":"博士","salary":"9.600万","stockAmount":"-","description":"周凌宏先生:1965年生,中国国籍,无境外永久居留权,教授,博士生导师,现任南方医科大学生物医学工程学院医疗仪器研究所所长、广东省放射诊断治疗设备工程技术研究中心主任。曾获国家科技进步二等奖1项、省部级科技成果奖7项、国家级教学成果二等奖和省级教学成果一等奖各1项;已取得授权发明专利6项。现主持国家重点研发计划“数字诊疗装备研发专项”项目,担任全国医用电器标准化技术委员会放射治疗核医学和放射剂量学设备分技术委员会(TC10/SC3)委员、中国仪器仪表学会医疗仪器分会常务理事、广东省医疗器械产业技术创新战略联盟秘书长、广东省生物医学工程学会副理事长、广东省生物医学工程学会医疗器械分会主任委员和医学物理分会副主任委员、广东省医疗仪器设备及器械标准化技术委员会(GDTC16)副主任委员、广东省药品监督管理局医疗器械专家委员会副主任委员等。现任健帆生物科技集团股份有限公司独立董事。","lastUpdated":"2020-04-28"},{"id":"健帆生物科技集团股份有限公司_崔松宁","group":"board","name":"崔松宁","title":"独立董事","isMale":true,"age":"53","degree":"本科","salary":"9.600万","stockAmount":"-","description":"崔松宁,男,1967年生,中国国籍,无境外永久居留权,1988年毕业于广东财经大学会计系审计专业,中国注册会计师、中国注册税务师、注册土地估价师、司法会计鉴定人、破产管理人。曾任珠海市第七届和第八届人民代表大会代表;现任中审众环会计师事务所(特殊普通合伙)珠海分所任执行合伙人,众环海华(珠海)税务师事务所有限公司任董事长,珠海金税科技有限公司任董事长,珠海航天信息科技有限公司任副董事长,珠海中拓正泰企业管理咨询有限公司任董事长,珠海派诺科技股份有限公司独立董事。","lastUpdated":"2020-04-28"},{"id":"健帆生物科技集团股份有限公司_彭小红","group":"supervisoryCommittee","name":"彭小红","title":"监事会主席","isMale":true,"age":"60","degree":"硕士","salary":"6.000万","stockAmount":"-","description":"彭小红先生:1960年生,中国国籍,无境外永久居留权,广东省委党校本科学历、中山大学企业管理专业研究生学历。历任丽珠集团团委书记、丽珠报主编、总经办副主任、人力资源总部总经理。现任珠江文化研究会策划部副部长、北师大物流管理学院客座讲师、广东星昊药业有限公司管理顾问。现任健帆生物科技集团股份有限公司监事会主席。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_方丽华","group":"supervisoryCommittee","name":"方丽华","title":"监事","isMale":false,"age":"46","degree":"大专","salary":"6.000万","stockAmount":"309.6万","description":"方丽华女士:1974年生,中国国籍,无境外永久居留权,高级物流管理师,毕业于中国药科大学,大专学历。曾任珠海丽珠集团南贸部、电子厂销售内勤,2007年至2016年12月期间任职于健帆生物科技集团股份有限公司,历任出纳、仓储物流部经理、总务部经理。现任健帆生物科技集团股份有限公司监事。","lastUpdated":"2020-04-28"},{"id":"健帆生物科技集团股份有限公司_陈耀红","group":"supervisoryCommittee","name":"陈耀红","title":"职工监事","isMale":true,"age":"41","degree":"本科","salary":"26.66万","stockAmount":"-","description":"陈耀红先生,1979年生,中国国籍,无境外永久居留权,2002年毕业于西北政法大学,本科学历。曾先后任职于山东省庆云县司法局、九州通医药集团股份有限公司、广东九州通医药有限公司。2013年加入健帆生物科技集团股份有限公司,现任健帆生物科技集团股份有限公司职工监事、法务部主管。","lastUpdated":"2020-04-02"},{"id":"健帆生物科技集团股份有限公司_董凡","group":"manager","name":"董凡","title":"总经理","isMale":true,"age":"50","degree":"硕士","salary":"210.1万","stockAmount":"3.508亿","description":"董凡先生:1970年生,中国国籍,无境外永久居留权,上海财经大学本科学历,中山大学企业管理专业研究生学历。1992年至1999年在珠海丽珠医药集团股份有限公司从事营销及管理工作,1999年进入健帆生物科技集团股份有限公司负责公司全面经营管理工作。曾获得国家科技进步二等奖、天津市科技进步二等奖、珠海市科技进步一等奖等多项荣誉。2011年,当选为珠海市人大代表。2012年,当选为中共广东省党代会代表。2016年,当选为珠海市工商联主席、珠海市总商会会长,荣获“广东省优秀中国特色社会主义事业建设者”荣誉称号。2017年,当选为中华全国工商业联合会执行委员、广东省工商业联合会(总商会)执行委员会副主席、珠海市人大常委会委员,入选“广东特支计划”科技创业领军人才、“科技部创新人才推进计划科技创新创业人才”,被珠海市政府聘为“珠海市决策咨询委员会顾问”。2018年,入选“国家万人计划科技创业领军人才”,当选为政协广东省委员会委员,获评“广东省五一劳动奖章”。现任健帆生物科技集团股份有限公司董事长、总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_张明渊","group":"manager","name":"张明渊","title":"董事会秘书","isMale":true,"age":"35","degree":"硕士","salary":"43.47万","stockAmount":"6.95万","description":"张明渊先生:1985年生,中国国籍,无境外永久居留权,中山大学本科学历、四川大学研究生学历。2008年至2016年5月任广东生益科技股份有限公司证券事务代表,2014年2月取得董事会秘书资格证书。2016年7月加入健帆生物科技集团股份有限公司,历任证券事务代表及证券部经理,现任健帆生物科技集团股份有限公司董事会秘书。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_曾凯","group":"manager","name":"曾凯","title":"副总经理","isMale":true,"age":"45","degree":"本科","salary":"100.9万","stockAmount":"53.6万","description":"曾凯先生:1975年生,中国国籍,无境外永久居留权,武汉工业大学本科学历。2008年进入健帆生物科技集团股份有限公司,历任采购供应部经理、企业管理部经理、人事行政中心总监、生产总监,现任健帆生物科技集团股份有限公司董事、副总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_唐先敏","group":"manager","name":"唐先敏","title":"副总经理","isMale":false,"age":"50","degree":"本科","salary":"137.6万","stockAmount":"2457万","description":"唐先敏女士:1970年生,中国国籍,无境外永久居留权,成都体育学院运动医学专业本科学历。曾先后任职于丽珠集团丽珠保健品厂、美国西尔药厂,从事营销工作。1999年8月加入健帆生物科技集团股份有限公司,历任办事处经理、大区经理、事业部副总监、市场总监。曾获得珠海市科技进步一等奖、珠海市“三八”红旗手、珠海市高层次人才。现任健帆生物科技集团股份有限公司董事、副总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_张广海","group":"manager","name":"张广海","title":"副总经理","isMale":true,"age":"56","degree":"硕士","salary":"72.41万","stockAmount":"557.1万","description":"张广海先生:1964年生,中国国籍,无境外永久居留权,齐齐哈尔大学本科学历,中山大学企业管理专业研究生学历,高级工程师。2001年加入健帆生物科技集团股份有限公司,历任生产部经理、总经理助理。曾获得国家科技进步二等奖、天津市科技进步二等奖、珠海市科技进步一等奖、珠海市高层次人才。担任全国医用体外循环设备标准化技术委员会委员,现任健帆生物科技集团股份有限公司董事、副总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_李得志","group":"manager","name":"李得志","title":"副总经理","isMale":true,"age":"54","degree":"本科","salary":"59.14万","stockAmount":"355.9万","description":"李得志先生:1966年生,中国国籍,无境外永久居留权,湖北大学本科学历。2005年进入健帆生物科技集团股份有限公司,健帆生物科技集团股份有限公司技术部经理、生产总监、质量总监、公司第三届董事会董事。曾获珠海市自主创新促进奖、珠海市科学技术进步奖二等奖、珠海市科学技术进步奖、珠海市高层次人才。现任健帆生物科技集团股份有限公司副总经理。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_吴爱军","group":"manager","name":"吴爱军","title":"副总经理","isMale":true,"age":"55","degree":"本科","salary":"--","stockAmount":"-","description":"吴爱军先生:1965年生,中国国籍,无境外永久居留权。1986年中国人民解放军白求恩军医学院毕业。历任北京军区某部队卫生队长兼主治医师、团党委常委、后勤处长兼后勤党委书记。历任国家药品监督管理局器械技术审评中心办公室主任、国家食品药品监督管理局医疗器械管理司研究监督处处长。现任健帆生物科技集团股份有限公司副总经理、首席战略官。","lastUpdated":"2020-05-11"},{"id":"健帆生物科技集团股份有限公司_何小莲","group":"manager","name":"何小莲","title":"财务总监","isMale":true,"age":"37","degree":"本科","salary":"--","stockAmount":"-","description":"何小莲先生:1983年生,中国国籍,无境外永久居留权,西南政法大学本科学历,中国注册会计师(非执业)。历任美的集团股份有限公司财务经理、上海美的生活家电销售有限公司财务总监、广东小熊电器股份有限公司财务总监;2017年10月至今任健帆生物财务中心总监,现任健帆生物科技集团股份有限公司财务总监。","lastUpdated":"2020-05-11"}],"companyName":"健帆生物科技集团股份有限公司","province":"广东省","englishName":"Jafron Biomedical Co Ltd","industry":"医药生物 — 医疗器械Ⅱ","website":"www.jafron.com","mainBusiness":"血液灌流相关产品的研发、生产与销售","productsName":["一次性使用血液灌流器","血液灌流机","一次性使用血浆胆红素吸附器","DX-10型血液净化机","血液透析粉液"],"actualController":"董凡","actualControllerSharePercentage":"43.99%","registeredCapital":"7.98亿元","employeeAmount":"1895","phone":"86-0756-3619693","location":"广东省珠海市香洲区高新区科技六路98号","chineseDescription":"健帆生物科技集团股份有限公司主要从事血液灌流相关产品的研发、生产与销售。主要产品有一次性使用血液灌流器（HA树脂血液灌流器）、血液灌流机、一次性使用血浆胆红素吸附器、DX-10型血液净化机。公司系国家高新技术企业，“高性能血液净化医用吸附树脂的创制”项目曾获“2009 年国家科技进步二等奖”，承担两项“国家重点新产品项目”、三项“国家级火炬计划项目”；被认定为“国家火炬计划重点高新技术企业”。","foundedDate":"1989-12-19","goPublicDate":"2016-08-02","companyHistory":"健帆生物科技集团股份有限公司系由健帆生物有限整体变更设立。\n　　2010年12月12日，健帆生物有限全体股东一致同意公司以截至2010年11月30日经审计的账面净资产值121,094,580.13元为基数折股6,600万股，其余55,094,580.13元计入资本公积，整体变更设立珠海健帆生物科技股份有限公司。本次整体变更出资经利安达会计师事务所有限责任公司珠海分所2010年12月15日出具的“利安达验字【2010】第B-1053”号《验资报告》及瑞华会计师事务所（特殊普通合伙）于2014年7月30日出具的瑞华核字[2014]40030033号《验资复核报告》验证足额到位。\n　　2010年12月31日，本公司在珠海市工商局完成注册登记变更手续，公司注册资本6,600万元。\n　　本公司前身为丽珠集团丽珠医用生物材料厂。丽珠生材厂股东会于2002年4月18日作出决议，同意将丽珠生材厂改制为珠海丽珠医用生物材料有限公司，丽珠生物有限的设立出资经珠海安德利联合会计师事务所2002年7月12日出具安德利验字（2002）第338-3号《验资报告》验证足额到位。\n　　2002年8月12日，丽珠生物有限在珠海市工商局完成注册登记，公司注册资本200万元。\n　　2011年3月11日，公司2011年第一次临时股东大会决议增加股本至7,500万元，新增股本由董凡、郭学锐、龙颖剑、黄河、唐先敏、郭爱国、张广海、张广宇、金瑞华、李洪明、旷怀仁、廖雪云、黄英、何峻青、易璟琳、肖赛凤、卢少章、李得志、王丽、杜鸿雁、钟建飞、杨兆禄、谈福珍、蒋娟、李峰、黄海燕、刘海南、方丽华、侯葵、万武卿、夏斌、陈晨、曹武峰、张慧君、王志超、张华、陈奕雄、郭鹏、周瑾、张广东、唐甲文、胡勇、陈爱国、张泽海、雷光荣、郎松、程立征、张清红、郭耀秋、胡戈、谢庆武、周辉、才建华、吴国秀、郭丽丽、骆雅红、徐杰、朱学军、陈京南、戴倩、张红、曾凯、唐嵘、郭延河、周志刚、王喜红、毕大武、侯怀信等以现金1,800万元缴纳。新增股本于2011年3月17日，经利安达会计师事务所有限责任公司利安达验字[2011]第B-1009号验资报告验证。2011年3月30日，完成工商变更登记手续，并换发了广东省珠海市工商行政管理局核发的《企业法人营业执照》，注册资本为7,500万元，注册号440400400012339。\n　　2013年3月，根据张广宇与杨晶签署的股权分割协议，张广宇名下持有的公司66.3711万股中的38万股股份归杨晶所有。\n　　2013年11月25日，根据公司2013年第三次临时股东大会决议，公司按每10股转增8股的比例，以原股份7,500万股为基数，以资本公积向全体股东转增股份总额6,000万股，每股面值1元，计增加股本6,000万元。\n　　转增股本于2013年12月12日，经瑞华会计师事务所（特殊普通合伙）出具瑞华验字[2013]第841A0005号验资报告验证。2013年12月30日，完成工商变更登记手续，并换发了广东省珠海市工商行政管理局核发的《企业法人营业执照》，注册资本为13,500万元，注册号440400400012339。\n　　2014年11月7日，根据公司2014年第三次临时股东大会决议，以资本公积、未分配利润向全体股东转增股份总额23,500万股，每股面值1元，计增加股本23,500万元。转增股本于2014年11月10日，经瑞华会计师事务所（特殊普通合伙）出具瑞华验字[2014]40030008号验资报告验证。2014年11月20日，完成工商变更登记手续，并换发了广东省珠海市工商行政管理局核发的《企业法人营业执照》，注册资本为37,000万元。\n　　经中国证券监督管理委员会（证监许可[2016]1460号）核准，经深圳证券交易所（深证上[2016]490号）同意，公司发行的人民币普通股股票于2016年8月2日在深圳证券交易所创业板上市，股票简称：“健帆生物”，股票代码：“300529”，发行采用网下向股票配售对象询价配售与网上向社会公众投资者定价发行相结合的方式，每股面值1元，发行价格为10.80元/股。公开发行合计4,200万股人民币普通股，首次公开发行后，健帆生物总股本为41,200万股。\n　　根据公司2017年第二次临时股东大会审议通过的《关于公司<2016年限制性股票激励计划（草案）>及其摘要的议案》和第二届董事会第二十四次会议决议，本次由192名限制性股票激励对象行权，实际行权数量为4,604,000股，本次行权于2017年3月6日完成验资，中国证券登记结算有限责任公司深圳分公司已完成核准登记。行权后注册资本变更为416,604,000元。此次增资已由立信会计师事务所（特殊普通合伙）信会师报字(2017)第ZC10116号验资报告验证。\n　　2017年9月14日，公司2017年第四次临时股东大会审议通过《关于回购注销部分限制性股票的议案》，因1名激励对象离职，同意回购其已获受但尚未解锁的限制性股票18,000股，回购价格为29.96元/股。截至2018年1月15日，已完成回购注销手续，注销完成后，公司股本变更为416,586,000元。\n　　2017年12月4日，公司第三届董事会第十四次会议审议通过了《关于公司2016年限制性股票激励计划预留部分授予事项的议案》。公司以2017年12月4日为授予日，向17名激励对象以16.55元/股的价格授予限制性股票激励计划预留部分共1,000,000股限制性股票。截至2018年1月11日止，公司已收到股权激励对象缴入的出资款人民币16,550,000.00元，经瑞华会计师事务所（特殊普通合伙）于2018年1月12日出具瑞华验字[2018]40030002号验资报告验证确认。授予限制性股票的上市日期为2018年1月23日，公司股本变更为417,586,000.00元。\n　　2018年6月11日，公司第三届董事会第十九次会议，审议通过了《关于回购注销部分限制性股票的议案》，公司回购注销2016年限制性股票激励计划首次授予的尚未解除限售的限制性股票25.456万股、2016年限制性股票激励计划预留授予的尚未解除限售的限制性股票5.5万股，本次回购注销的限制性股票数量共计30.956万股。经瑞华会计师事务所（特殊普通合伙）出具瑞华验字[2018]40030009号验资报告验证确认。公司股本变更为417,276,440.00元。\n　　2018年10月29日，经公司2018年度第二次临时股东大会审议通过《关于变更公司名称的议案》，公司名称变更为“健帆生物科技集团股份有限公司”，并于2018年11月2日完成工商变更登记。\n　　2019年4月11日，公司第三届董事会第三十三次会议，审议通过了《关于2017年股票期权激励计划首次授予股票期权第一个行权期可行权的议案》，公司首次授予股票期权的第一个行权条件已满足，本次行权股份1,523,976股，其中1,073,255股每股行权价格为34.19元，450,721股每股行权价格为33.59元，本次行权后，股本变更为人民币418,800,416.00元。\n    2019年6月26日，公司2019年第二次临时股东大会决议，审议通过了《关于回购注销部分限制性股票的议案》，本次回购注销股份206,080股，回购共计应支付限制性股票回购款人民币5,341,405.80元，本次回购注销股份后的股本为人民币418,612,760.00元。经瑞华会计师事务所（特殊普通合伙）出具瑞华验字[2019]40030002号验资报告验证确认，公司股本变更为418,612,760.00元。\n    截至2019年12月31日止，公司首次授予股票期权的200名激励对象全部行权，行权股份累计1,593,000股，股本变更为人民币418,663,360.00元。收起▲","shareholders":[],"englishDescription":"Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company鈥檚 products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company鈥檚 products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company鈥檚 products are applied in 31 provinces, more than 3000 hospitals in China.","englishIndustry":"Medical Equipment & Supplies","Price to earnings (ttm)":"92.74","Price to sales (ttm)":"38.63","Price to book (mrq)":"24.88","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"0.00","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"29.14","Return on equity (ttm)":"25.44","Income statement":{"Revenue":"1,431.82","Total revenue":"1,431.82","Cost of revenue, total":"197.40","Gross profit":"1,234.42","Selling/general/admin. expenses, total":"550.03","Research & development":"66.61","Depreciation/amortization":"13.40","Interest exp.(inc.),net-operating, total":"(44.34)","Unusual expense (income)":"1.40","Other operating expenses, total":"(31.65)","Total operating expense":"752.84","Operating income":"678.98","Other, net":"(7.69)","Net income before taxes":"671.28","Provision for income taxes":"102.59","Net income after taxes":"568.69","Minority interest":"2.13","Net income before extra. items":"570.82","Net income":"570.82","Income available to com excl extraord":"570.82","Income available to com incl extraord":"570.82","Diluted net income":"570.82","Diluted weighted average shares":"785.91","Diluted eps excluding extraord items":"0.73","Dps - common stock primary issue":"0.47","Diluted normalized eps":"0.73","Gain (loss) on sale of assets":"(0.03)"},"Balance sheet":{"Cash":"0.05","Cash & equivalents":"1,271.68","Cash and short term investments":"1,271.73","Accounts receivable - trade, net":"158.30","Total receivables, net":"171.32","Total inventory":"92.31","Prepaid expenses":"24.38","Total current assets":"1,559.74","Property/plant/equipment, total - gross":"809.68","Accumulated depreciation, total":"(92.85)","Property/plant/equipment, total - net":"716.83","Goodwill, net":"44.07","Intangibles, net":"48.05","Long term investments":"100.79","Other long term assets, total":"25.18","Total assets":"2,494.66","Accounts payable":"32.83","Accrued expenses":"81.31","Notes payable/short term debt":"0.00","Other current liabilities, total":"148.49","Total current liabilities":"262.63","Total long term debt":"0.00","Total debt":"0.00","Deferred income tax":"0.81","Minority interest":"28.06","Other liabilities, total":"60.68","Total liabilities":"352.19","Common stock, total":"418.66","Additional paid-in capital":"606.05","Retained earnings (accumulated deficit)":"1,172.79","Treasury stock - common":"(59.65)","Other equity, total":"4.62","Total equity":"2,142.47","Total liabilities & shareholders' equity":"2,494.66","Total common shares outstanding":"790.75","Tangible book value per share, common eq":"2.59","Other current assets, total":"5.00"},"Cash flow":{"Cash receipts":"1,598.23","Cash payments":"(195.52)","Cash taxes paid":"(275.48)","Changes in working capital":"(543.74)","Cash from operating activities":"583.50","Capital expenditures":"(220.67)","Other investing cash flow items, total":"23.55","Cash from investing activities":"(197.12)","Financing cash flow items":"55.57","Total cash dividends paid":"(251.01)","Cash from financing activities":"(195.44)","Foreign exchange effects":"(0.00)","Net change in cash":"190.93"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"73.40","52 Week High":"79.83","52 Week Low":"29.47","Pricing date":"","10 Day Average Trading Volume":"8.63","Market Capitalization":"58,543.61","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"183.12","Beta":"0.83","1 Day Price Change":"-0.12","13 Week Price Return (Daily)":"25.39","26 Week Price Return (Daily)":"72.64","5 Day Price Return (Daily)":"6.38","52 Week Price Return (Daily)":"136.61","Year To Date Price Return (Daily)":"94.13","Month to Date Price Return (Daily)":"5.61","Price Relative to S&P500 (4 Week)":"0.55","Price Relative to S&P500 (13 Week)":"-1.42","Price Relative to S&P500 (26 Week)":"35.22","Price Relative to S&P500 (52 Week)":"60.80","Price Relative to S&P500 (YTD)":"48.47"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.73","EPS excl. Extra Items (TTM)":"0.79","EPS Normalized (Annual)":"0.73","Revenue per Share (Annual)":"1.82","Revenue per Share (TTM)":"1.92","Book Value (Per Share Annual)":"2.71","Book Value (Per Share Quarterly)":"2.95","Tangible Book Value (Per Share Annual)":"2.59","Tangible Book Value (Per Share Quarterly)":"2.83","Cash Per Share (Per Share Annual)":"1.61","Cash Per Share (Per Share Quarterly)":"1.75","Cash Flow (Per Share Annual)":"0.76","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.47","Dividends (Per Share TTM)":"0.47","EBITD (Per Share TTM)":"0.90","EPS Basic excl. Extra Items (Annual)":"0.73","EPS Basic excl. Extra Items (TTM)":"0.79","EPS incl. Extra Items (Annual)":"0.73","EPS incl. Extra Items (TTM)":"0.79","Free Cash Flow (Per Share TTM)":"0.53","Dividend (Per Share 5Y)":"--"},"Valuation":{"P/E excl. Extra Items (Annual)":"101.06","P/E excl. Extra Items (TTM)":"92.74","P/E Normalized (Annual)":"100.85","Price to sales (Annual)":"40.89","Price to sales (TTM)":"38.63","Price to Tangible Book (Annual)":"28.55","Price to Tangible Book (Quarterly)":"26.12","Price to Free Cash Flow (Per Share Annual)":"523.58","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"139.20","Price to Book (Annual)":"27.09","Price to Book (Quarterly)":"24.88","P/E Basic excl. Extra Items (TTM)":"62.95","P/E excl. Extra Items High (TTM)":"99.87","P/E excl. Extra Items Low (TTM)":"42.64","P/E incl. Extra Items (TTM)":"92.74","Net Debt (Interim)":"-1,380.89","Net Debt (Annual)":"-1,271.73","Dividend Yield (5Y)":"--","Dividend Yield":"0.65","Current Dividend Yield (TTM)":"0.65"},"Financial Strength":{"Free Cash Flow (Annual)":"111.81","Current Ratio (Annual)":"5.94","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"66.01","Quick Ratio (Annual)":"5.59","Total Debt/Total Equity (Annual)":"0.00","Current EV/Free Cash Flow (Annual)":"451.89","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"5.93","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"5.62","Total Debt/Total Equity (Quarterly)":"0.00","Free Cash Flow (TTM)":"420.59","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"60.22"},"Margins":{"Gross Margin (Annual)":"86.21","Gross Margin (TTM)":"84.73","Net Profit Margin % (Annual)":"39.72","Net Profit Margin (TTM)":"41.12","Operating Margin (Annual)":"47.42","Operating Margin (TTM)":"49.71","Pretax Margin (TTM)":"48.49","Pretax Margin (Annual)":"46.88","Operating Margin (5Y)":"46.50","Pretax Margin (5Y)":"46.59","Free Operating Cash Flow/Revenue (5Y)":"10.05","Free Operating Cash Flow/Revenue (TTM)":"27.75","Gross Margin (5Y)":"85.03","Net Profit Margin (5Y)":"39.26"},"Management Effectiveness":{"Return on Assets (Annual)":"25.02","Return on Equity (TTM)":"25.44","Return on Average Equity (Annual)":"29.72","Return on Average equity (TTM)":"30.04","Return on Investment (Annual)":"28.77","Return on Investment (TTM)":"29.14","Return on Average Assets (5Y)":"22.82","Return on Average Equity (5Y)":"27.05","Return on Investment (5Y)":"26.12","Asset Turnover (Annual)":"0.63","Asset Turnover (TTM)":"0.62","Inventory Turnover (Annual)":"2.57","Inventory Turnover (TTM)":"3.02","Net Income/Employee (Annual)":"329,105.00","Net Income/Employee (TTM)":"328,852.50","Receivables Turnover (Annual)":"10.03","Receivables Turnover (TTM)":"8.78","Revenue/Employee (Annual)":"828,599.20","Revenue/Employee (TTM)":"799,752.80"},"Growth":{"Revenue Growth (Quarterly YoY)":"28.36","Revenue Growth Rate (5Y)":"31.01","EPS Growth (Quarterly YoY)":"40.46","EPS Growth (TTM YoY)":"40.68","EPS Growth Rate (5Y)":"26.11","Dividend Growth Rate (3Y)":"65.10","Revenue Growth (TTM YoY)":"37.14","Revenue Growth (Per Share 5Y)":"28.12","Revenue Growth Rate (3Y)":"38.10","EPS Growth Rate (3Y)":"38.45","Book Value Growth Rate (Per Share 5Y)":"33.31","Tangible Book Value Total Equity CAGR (5Y)":"36.75","Capital Spending growth rate 5 year":"27.97","EBITDA CAGR (5Y)":"30.98","EBITDA Interim CAGR (5Y)":"--","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"--","Net Profit Margin Growth Rate (5Y)":"-1.64"},"Income Statement":{"Revenue (Annual)":"1,431.82","Revenue (TTM)":"1,515.53","EBITD (Annual)":"665.83","EBITD (TTM)":"708.46","Earnings Before Taxes (Annual)":"671.28","Earnings Before Taxes (TTM)":"734.95","Net Income to Common (Annual)":"570.82","Net Income to Common (TTM)":"625.66","Earnings Before Taxes Normalized (Annual)":"672.68","Net Income Available to Common Normalized (Annual)":"572.01","Diluted Normalized EPS excl. Extra Items (TTM)":"0.79"}}}